Nationwide Recall Issued for Common Antidepressant Due to Potential Cancer Risk
A nationwide recall has been issued for thousands of bottles of duloxetine delayed-release capsules after federal regulators identified elevated levels of a potentially cancer-causing impurity in the medication.
According to the U.S. Food and Drug Administration’s enforcement report, the recall affects 14,729 bottles of Duloxetine Delayed-Release Capsules, USP, 30 mg. The product was manufactured by Towa Pharmaceutical Europe and distributed nationwide by Breckenridge Pharmaceuticals. The FDA classified the action as a Class II recall, indicating that use of the product may cause temporary or medically reversible health consequences, while the likelihood of serious adverse health effects is considered remote.
The recalled product was distributed in 1,000-count bottles under NDC 51991-747-10. The affected lot number is 241180C, with an expiration date of April 2027. The recall was initiated on June 4, 2026, and remains ongoing.
What Triggered the Recall
The recall was initiated because testing identified elevated levels of N-nitroso-duloxetine, an impurity that exceeded the FDA’s recommended interim limit.
N-nitroso-duloxetine belongs to a broader group of compounds known as nitrosamines. Over the past several years, health regulators around the world have increased scrutiny of nitrosamine contamination after similar impurities were detected in a variety of medications.
According to the FDA, exposure to nitrosamine impurities above acceptable limits over extended periods may increase the risk of cancer. However, regulators note that cancer risk is generally associated with the amount and duration of exposure rather than short-term use.
Importantly, health authorities have not stated that duloxetine itself causes cancer. The concern centers on impurity levels found in specific batches that exceed established safety thresholds.
A Medication Used by Millions
Duloxetine is a widely prescribed antidepressant commonly used to treat major depressive disorder and generalized anxiety disorder. It is also prescribed for certain chronic pain conditions, including diabetic nerve pain and fibromyalgia.
Because the medication is often taken for extended periods, even small manufacturing issues can draw significant regulatory attention. Long-term medications receive particularly close scrutiny when impurities with potential cancer risks are detected, as prolonged exposure is one of the key factors regulators consider when evaluating safety concerns.
The FDA’s action reflects the agency’s broader effort to identify and remove products that fail to meet quality standards before they pose a larger risk to patients. In many cases, recalls are issued out of an abundance of caution rather than in response to documented injuries.
For patients currently taking duloxetine, healthcare experts continue to emphasize the importance of consulting a physician or pharmacist before making any changes to treatment.
The Latest in an Ongoing Industry-Wide Issue
While the 2026 recall has generated fresh attention, it is not the first time duloxetine products have been recalled because of elevated levels of N-nitroso-duloxetine.
In 2024, separate recalls involving duloxetine delayed-release capsules from other manufacturers were also initiated after the same impurity was found above recommended limits. Those recalls involved significantly larger quantities of product and similarly resulted in Class II classifications from the FDA.
The recurrence of these recalls highlights a broader challenge facing the pharmaceutical industry. Since nitrosamine contamination first emerged as a major regulatory concern several years ago, manufacturers and health agencies have expanded testing programs and reviewed manufacturing processes across numerous categories of drugs.
Patients who have questions about their medication should consult their pharmacist or healthcare provider to determine whether their prescription may be affected and to discuss appropriate next steps.
